Alkermes plc ALKS announced the initiation of the phase II Vibrance-2 study, evaluating its novel, investigational, oral orexin 2 receptor agonist ALKS 2680 in adults with narcolepsy type 2 (NT2). The ...
Posters presented at the SLEEP 2023 conference showed that transition between medications was easy but 1 medication felt more effective to patients. Switching from high-sodium oxybate (SXB) to ...
A new Northwestern Medicine study has demonstrated a new way to treat narcolepsy-related nightmares. The scientists combined cognitive behavioral therapy (CBT) and lucid dreaming to help patients in a ...
People with certain types of long-term sleep disorders may use a medicine called sodium oxybate to help treat their condition. This medicine is taken at night and may help people with narcolepsy to ...
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that data from the Phase 2 study of orexin receptor 2 (OX2R) agonist TAK-994 in patients with narcolepsy ...
– Alixorexton is the First Oral Orexin 2 Receptor Agonist to Demonstrate Efficacy in a Large Phase 2 Study in Patients With Narcolepsy Type 2, Supporting Advancement to Phase 3 – – Alixorexton Met the ...
ZURICH, SWITZERLAND / ACCESSWIRE / March 27, 2023 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and ...
HELSINKI, Dec 22 (Reuters) - A Helsinki court ordered on Thursday payment of indemnities to a new group of Finnish patients who were found to have caught the sleep disorder narcolepsy as a side effect ...
– Alixorexton Demonstrated Clinically Meaningful and Statistically Significant Improvements in Wakefulness at All Doses Tested Compared to Placebo in Patients With Narcolepsy Type 1 – – Alixorexton ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results